Tag
Pharmaceuticals
11 articles
AstraZeneca Explored Acquisition of Bristol Myers Squibb in $400 Billion Deal
A combination would create one of the world's largest drugmakers and expand AstraZeneca's footprint in the United States.
Eli Lilly's Retatrutide FDA Bid Targets $25B Peak Sales in $100B Obesity Market
Lilly's triple-receptor weight-loss drug retatrutide heads to FDA with a 24 percent efficacy edge over rivals and a $1,200 price target from JPMorgan.
Trump's 100% Generic Drug Tariffs: Who Wins, Who Pays
President Trump's plan to impose 100 percent tariffs on imported generic drugs by 2028 would double prices for medications that fill nine of 10 U.S. prescriptions.
TrumpRx Adds Hundreds of Generics, Escalating Drug Cost Battle
The platform's expansion to 300 new generic drugs directly challenges Big Pharma and pharmacy benefit managers, aiming to cut consumer costs
Trump Flags Ebola Concerns—Pharma Stocks Rise on Federal Spending Hopes
Presidential remarks at White House briefing trigger market speculation about new infectious disease funding
WHO Ebola Emergency Unlocks Billions for Merck, J&J Vaccines
Global health declaration triggers immediate funding release as pharmaceutical companies prepare for major procurement contracts from U.S. and international agencies
UCB $2.2 Billion Buy Signals M&A Resilience Amid Stable Rates
Belgian pharma group UCB's substantial acquisition of Candid Therapeutics underscores how prevailing interest rate conditions and broader economic stability are shaping corporate M&A strategies and capital deployment.
Supreme Court Weighs Mifepristone Access: Drugmakers Brace for Market Shift, Regulatory Fallout
The nation's highest court faces a critical decision on mail-order abortion pills, potentially reshaping the pharmaceutical market and igniting a new wave of political spending.
Sanders Forces GOP Vote on Trump Drug Deals, Exposing Pharma Cash Ties
Senator Bernie Sanders is compelling Senate Republicans to take a public stand on President Trump's pharmaceutical pricing agreements, aiming to highlight the industry's significant lobbying influence and campaign contributions.
Pharma Onshoring Mandate: Trump's 100% Tariff Threat Reshapes Drug Sector
The White House's unprecedented tariff threat on branded pharmaceuticals forces a reckoning for global drugmakers, demanding domestic manufacturing or steep levies.
Targeted Pharma Levies Trigger Credit Spread Scrutiny, Sector Volatility
President Trump's selective pharmaceutical levies, exempting cooperating firms, introduce a nuanced risk profile for branded drug manufacturers, prompting re-evaluation of sector-specific credit and equity exposures without broad market contagion.